DLEC1 Antibody (D-11): sc-393183

DLEC1 Antibody (D-11) is a mouse monoclonal IgG1 kappa light chain antibody that detects DLEC1 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). DLEC1 (D-11) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. DLEC1 protein, known as deleted in lung and esophageal cancer protein 1, plays a crucial role as a tumor suppressor, particularly in various carcinomas where expression is often lost due to chromosomal deletions on chromosome 3p. This 1,755 amino acid cytoplasmic protein is primarily located in the cytoplasm, which is significant because cytoplasmic localization is essential for function in inhibiting cell proliferation and invasion. Cytoplasmic presence of DLEC1 enables interaction with other signaling pathways that regulate cell growth and apoptosis, thereby contributing to tumor-suppressive properties. Introduction of DLEC1 cDNA into cancer cell lines has been shown to reduce invasiveness and suppress cell growth, highlighting potential as a therapeutic target. Methylation of DLEC1 promoter has been associated with poor prognosis in non-small cell lung carcinoma and nasopharyngeal carcinoma, underscoring importance in cancer biology. With highest expression levels found in kidney and prostate, DLEC1 exists in three isoforms due to alternative splicing, which may further influence functional roles in different tissues and cancer types.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

DLEC1 Antibody (D-11) References:

1. Molecular cloning of a candidate tumor suppressor gene, DLC1, from chromosome 3p21.3.  |  Daigo, Y., et al. 1999. Cancer Res. 59: 1966-72. PMID: 10213508
2. DNA variants of DLC-1, a candidate tumor suppressor gene in human hepatocellular carcinoma.  |  Park, SW., et al. 2003. Int J Oncol. 23: 133-7. PMID: 12792785
3. [Study of DLC1 gene expression in nasopharyngeal carcinoma].  |  Peng, H., et al. 2002. Zhonghua Er Bi Yan Hou Ke Za Zhi. 37: 454-7. PMID: 12966809
4. Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer.  |  Kwong, J., et al. 2006. Neoplasia. 8: 268-78. PMID: 16756719
5. Epigenetic inactivation of the deleted in lung and esophageal cancer 1 gene in nasopharyngeal carcinoma.  |  Kwong, J., et al. 2007. Genes Chromosomes Cancer. 46: 171-80. PMID: 17099870
6. The tumor suppressor gene DLEC1 is frequently silenced by DNA methylation in hepatocellular carcinoma and induces G1 arrest in cell cycle.  |  Qiu, GH., et al. 2008. J Hepatol. 48: 433-41. PMID: 18191269
7. DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma.  |  Seng, TJ., et al. 2008. Br J Cancer. 99: 375-82. PMID: 18594535
8. Aberrant methylation of p16, DLEC1, BLU and E-cadherin gene promoters in nasopharyngeal carcinoma biopsies from Tunisian patients.  |  Ayadi, W., et al. 2008. Anticancer Res. 28: 2161-7. PMID: 18751390
9. DLEC1, a 3p tumor suppressor, represses NF-κB signaling and is methylated in prostate cancer.  |  Zhang, L., et al. 2015. J Mol Med (Berl). 93: 691-701. PMID: 25648635
10. DLEC1 is not silenced solely by promoter methylation in head and neck squamous cell carcinoma.  |  Seven, D., et al. 2015. Gene. 563: 83-6. PMID: 25746324
11. Clinicopathological Significance and Diagnostic Value of DLEC1 Hypermethylation in Lung Cancer: A Meta-analysis.  |  Li, X., et al. 2019. J Nippon Med Sch. 86: 62-69. PMID: 31130567
12. Dlec1 is required for spermatogenesis and male fertility in mice.  |  Okitsu, Y., et al. 2020. Sci Rep. 10: 18883. PMID: 33144677

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-DLEC1 Antibody (D-11) has 0 citations in a variety of scientific publications.

Primary antibodies like Anti-DLEC1 Antibody (D-11) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

DLEC1 Antibody (D-11) Specifications

Alternate Product Name: DLEC1

Product Clone Name: D-11

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 320-349

Epitope Target: DLEC1

Epitope Species: human

Product Reactivity/Detection: DLEC1

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 0 citations in various scientific publications

Available Conjugates/Forms for DLEC1 Antibody (D-11): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, P: Blocking Peptide, PE: Phycoerythrin